• Research & Development

  Experimental PAH Treatment VI-0106 Shows Potential in Phase 1 Study

  Posted by Pulmonary Hypertension News Moderator on July 16, 2018 at 5:27 pm

  Vivus Biopharmaceuticals’ investigative therapy VI-0106 for the treatment of PAH showed a favorable pharmacokinetic profile in healthy volunteers in a Phase 1 trial.

  Read more about this study here: Vivus’ Experimental PAH Therapy VI-0106 Shows Potential in Phase 1 Study

  What are your thoughts on this news?

  replied 5 years, 10 months ago 1 Member · 0 Replies
• 0 Replies

Log In to Reply